Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.57 |
| ▸ | PPARD | Q03181 | 4/20 | 0.56 |
| ▸ | PPARG | P37231 | 3/20 | 0.56 |
| ▸ | PPARA | Q07869 | 3/20 | 0.56 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.50 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6353598 | 0.87 | PPARD (0.54) | CNR2PPARDPPARGPPARAPLA2G2A | |
| SCHEMBL6346110 | 0.81 | PPARD (0.52) | CNR2PPARDPPARGPPARAPLA2G2A | |
| SCHEMBL3386836 | 0.80 | LTB4R (0.66) | CNR2PPARDPPARGPPARAPLA2G2A | |
| SCHEMBL9036015 | 0.79 | CNR1 (0.74) | CNR2CNR1 | |
| SCHEMBL3203412 | 0.78 | SERPINE1 (0.64) | CNR2PPARDPPARGPPARAPLA2G2A | |
| SCHEMBL7679573 | 0.76 | SERPINE1 (0.59) | PPARDPPARGPPARAPLA2G2ALTB4R | |
| SCHEMBL8166905 | 0.75 | PPARD (0.74) | CNR2PPARDPPARGPPARAPLA2G2A | |
| SCHEMBL13930965 | 0.75 | PPARD (0.77) | CNR2PPARDPPARGPPARAPLA2G2A | |
| SCHEMBL5894096 | 0.74 | PLA2G2A (0.56) | PPARDPPARGPPARAPLA2G2ALTB4R | |
| SCHEMBL11904002 | 0.73 | CNR2 (0.69) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153751-A1 | Inhibitors of phospholipase enzymes | AMERICAN HOME PRODUCTS CORPORATION | 2003-08-14 | — | — | US | claimed |
| CN-1299347-A | Inhibitor of phospholipase enzymes | GENETICS INST (US) | 2001-06-13 | — | — | CN | claimed |
| EP-1056719-A2 | INHIBITORS OF PHOSPHOLIPASE ENZYMES | GENETICS INSTITUTE, INC. (US) | 2000-12-06 | — | — | EP | claimed |
| WO-1999043651-A2 | INHIBITORS OF PHOSPHOLIPASE ENZYMES | GENETICS INSTITUTE, INC. (US) | 1999-09-02 | — | — | WO | claimed |
| US-6916841-B2 | Inhibitors of phospholipase enzymes | GENETICS INSTITUTE, LLC (US) | 2005-07-12 | — | — | US | disclosed |
| US-6828344-B1 | Direct inhibition of the activity of phospholipase A2 has been suggested as a useful mechanism for a therapeutic agent for inflammation | GENETICS INSTITUTE, LLC | 2004-12-07 | — | — | US | disclosed |
| US-20030153751-A1 | Inhibitors of phospholipase enzymes | AMERICAN HOME PRODUCTS CORPORATION | 2003-08-14 | — | — | US | disclosed |
| EP-1056719-A2 | INHIBITORS OF PHOSPHOLIPASE ENZYMES | GENETICS INSTITUTE, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043651-A2 | INHIBITORS OF PHOSPHOLIPASE ENZYMES | GENETICS INSTITUTE, INC. (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153751-A1 | Inhibitors of phospholipase enzymes | PLA2G4C, PLA2G4B, PLA2G4A | CNR2 789/4885PPARD 1392/4885PPARG 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.